This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ABM Industries Stock Rises 16% in Six Months: Here's Why
by Zacks Equity Research
ABM's resilient services and sustainability focus have driven strong earnings, boosted by key acquisitions and demand in essential sectors.
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
by Zacks Equity Research
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
Reasons to Add Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS's strong product line and focus on R&D raise optimism about the stock.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raise optimism about the stock.
SYK Stock May Gain From Completion of Vertos Medical Acquisition
by Zacks Equity Research
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
Is HealthEquity Stock a Buy Now Amid Strength in HSAs?
by Zacks Equity Research
HQY's strong quarterly results and solid top-line growth raise optimism about the stock.
ITGR Shares Gain on the Divestiture of Its Non-Medical Business Line
by Zacks Equity Research
Integer Holdings announces to divest its Electrochem business to Ultralife for $50 million in cash.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
by Zacks Equity Research
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
PDCO Shares Gain Following New Deals to Boost Animal Health Business
by Zacks Equity Research
Patterson Companies announces to invest in two separate businesses to boost its animal health business.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.
Accenture's Q4 Earnings & Revenues Beat Estimates, Increase Y/Y
by Zacks Equity Research
ACN's fourth-quarter fiscal 2024 earnings and revenues increase year over year.
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
by Zacks Equity Research
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.
Reasons to Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, stiff competition and escalating costs are concerning.
ITGR Shares May Gain on the Completion of Irish Facility Expansions
by Zacks Equity Research
Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.
Stryker Shares May Gain on the Completion of the Acquisition of NICO
by Zacks Equity Research
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
by Zacks Equity Research
Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.
Here's Why Hold Strategy is Apt for ABM Industries Stock Now
by Zacks Equity Research
ABM has consistently demonstrated its commitment to rewarding shareholders through dividends and share buybacks.
Here's Why You Should Retain McKesson Stock in Your Portfolio Now
by Zacks Equity Research
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool
by Zacks Equity Research
GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based amyloid imaging.
CAH Stock May Gain Following the Distribution Agreement With Telix
by Zacks Equity Research
Cardinal Health and Telix announce an agreement selecting the former as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's Zircaix.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
NSPR Stock Declines Despite PMA Application Submission for CGuard
by Zacks Equity Research
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
by Zacks Equity Research
CVRx announces the publication of positive study data for its Barostim therapy.
Merit Medical Gains 26.4% Year to Date: What's Driving the Stock?
by Zacks Equity Research
MMSI's shares gain on the back of strength in its Cardiovascular segment and a robust product portfolio.
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
by Zacks Equity Research
Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.